Comparison of Cyfra 21-1 and SCC assays in head and neck tumours

被引:32
作者
Banal, A
Hacene, K
Berthelot-Ruff, E
Mahé, E
Fontana, X
Pichon, MF
机构
[1] Ctr Rene Huguenin Lutte Canc, Lab Oncobiol, F-92210 St Cloud, France
[2] Ctr Rene Huguenin Lutte Canc, Nucl Med Serv, F-92210 St Cloud, France
[3] Ctr Rene Huguenin Lutte Canc, Serv Stat Med, F-92210 St Cloud, France
[4] Ctr Rene Huguenin Lutte Canc, Serv Otorhinolaryngol, F-92210 St Cloud, France
[5] Ctr Antoine Lacassagne, Nucl Med Serv, F-06054 Nice, France
关键词
Cyfra; 21-1; head and neck tumours; SCC;
D O I
10.1159/000030152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with head and neck tumours (HNT) have a high risk of early locoregional relapse that is difficult to diagnose. This study evaluated the usefulness of the serum Cyfra 21-1 assay compared to squamous cell carcinoma antigen (SCC) assay for monitoring such patients. Three hundred and twelve HNT patients, including 204 newly diagnosed patients, were followed up for a median of 446 days with serial serum assays for SCC and Cyfra 21-1. Untreated patients showed SCC and Cyfra 21-1 serum levels correlated with each other: concentration was correlated to clinical stage, tumour size (as T1 + T2 vs. T3 + T4) and nodal status. Cyfra 21-1, but not SCC, was related to the presence of metastases and the primary tumour site, with a univariate prognostic value for disease-free survival (p = 0.015). Cox's regression analysis showed that only Cyfra 21-1 was associated with a risk of relapse (p = 0.027). The random coefficient growth curve model applied to serial SCC and Cyfra 21-1 measurements of 111 patients showed that only Cyfra 21-1 exhibited a significant difference between patients with and without relapses. We found Cyfra 21-1 to be more closely related to initial clinical data and disease evolution than SCC, and therefore propose the use of Cyfra 21-1 for monitoring head and neck cancers. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 22 条
  • [1] BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13
  • [2] COPPER MP, 1993, CANCER, V71, P825, DOI 10.1002/1097-0142(19930201)71:3<825::AID-CNCR2820710327>3.0.CO
  • [3] 2-X
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] CUSUM ANALYSIS OF THE SCC ANTIGEN IN PATIENTS WITH HEAD AND NECK-CANCER
    DAMICO, F
    SNYDERMAN, CH
    WAGNER, R
    NERELLA, NG
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1995, 16 (04) : 242 - 246
  • [6] DOWECK I, 1995, ARCH OTOLARYNGOL, V121, P177
  • [7] Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy
    Ho, S
    Leung, WT
    Yuen, J
    Johnson, PJ
    [J]. ORAL ONCOLOGY, 1996, 32B (06): : 377 - 380
  • [8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [9] Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients
    Kawamata, H
    Uchida, D
    Nakashiro, K
    Hino, S
    Omotehara, F
    Yoshida, H
    Sato, R
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) : 448 - 452
  • [10] Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer
    Krimmel, M
    Hoffmann, J
    Krimmel, C
    Cornelius, CP
    Schwenzer, N
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 1998, 26 (04) : 243 - 248